CVR number 39888041
Industry 46.4610 Wholesale of pharmaceutical goods

Ypsomed ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/3
2020
2021/3
2021
2022/3
2022
2023/3
2023
2024/3
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  3.3% 3.1% 3.9% 2.7% 2.5%  
Credit score (0-100)  56 56 49 60 61  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/3
2020
2021/3
2021
2022/3
2022
2023/3
2023
2024/3
Net sales  0 0 0 0 0  
Gross profit  2,471 2,547 2,665 2,838 4,195  
EBITDA  125 149 152 255 466  
EBIT  125 149 152 255 466  
Pre-tax profit (PTP)  108.5 119.9 136.3 258.0 454.5  
Net earnings  82.1 92.2 105.3 199.4 322.9  
Pre-tax profit without non-rec. items  108 120 136 258 455  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/3
2020
2021/3
2021
2022/3
2022
2023/3
2023
2024/3
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  3,801 3,893 3,999 4,198 4,521  
Interest-bearing liabilities  1,103 382 231 619 633  
Balance sheet total (assets)  6,047 5,500 5,134 6,991 7,606  
Net Debt  318 -454 -165 -1,803 -739  
 
See the entire balance sheet

Volume 
2019
2020/3
2020
2021/3
2021
2022/3
2022
2023/3
2023
2024/3
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,471 2,547 2,665 2,838 4,195  
Gross profit growth  55.5% 3.1% 4.6% 6.5% 47.8%  
Employees  6 3 3 3 5  
Employee growth %  200.0% -50.0% 0.0% 0.0% 66.7%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  6,047 5,500 5,134 6,991 7,606  
Balance sheet change%  -9.8% -9.0% -6.7% 36.2% 8.8%  
Added value  125.3 148.6 151.8 255.2 465.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  2.0 3.0 4.0 5.0 5.0  

Profitability 
2019
2020/3
2020
2021/3
2021
2022/3
2022
2023/3
2023
2024/3
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  5.1% 5.8% 5.7% 9.0% 11.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  2.0% 2.6% 3.0% 4.5% 6.6%  
ROI %  2.3% 3.2% 3.8% 6.0% 9.6%  
ROE %  2.2% 2.4% 2.7% 4.9% 7.4%  

Solidity 
2019
2020/3
2020
2021/3
2021
2022/3
2022
2023/3
2023
2024/3
Equity ratio %  62.9% 70.8% 77.9% 60.0% 59.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  253.6% -305.6% -108.7% -706.7% -158.6%  
Gearing %  29.0% 9.8% 5.8% 14.7% 14.0%  
Net interest  0 0 0 0 0  
Financing costs %  1.0% 3.9% 8.1% 3.0% 3.9%  

Liquidity 
2019
2020/3
2020
2021/3
2021
2022/3
2022
2023/3
2023
2024/3
Quick Ratio  2.8 3.4 4.4 2.5 2.4  
Current Ratio  2.9 3.4 4.5 2.5 2.5  
Cash and cash equivalent  785.5 836.5 396.4 2,421.8 1,372.0  

Capital use efficiency 
2019
2020/3
2020
2021/3
2021
2022/3
2022
2023/3
2023
2024/3
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  3,953.4 3,893.3 3,998.6 4,198.0 4,520.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/3
2020
2021/3
2021
2022/3
2022
2023/3
2023
2024/3
Net sales / employee  0 0 0 0 0  
Added value / employee  21 50 51 85 93  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  21 50 51 85 93  
EBIT / employee  21 50 51 85 93  
Net earnings / employee  14 31 35 66 65